June 13, 2018
SBP Doses First Patients in 2nd Clinical Study of SBP-101
SUN BIOPHARMA, INC. DOSES FIRST PATIENTS IN SECOND CLINICAL STUDY OF SBP-101 FOR PANCREATIC DUCTAL ADENOCARCINOMA
- After Successful Completion of the Phase 1 Dose Escalation/Safety Study of SBP-101, New Combination Study Opens for Previously Untreated Metastatic Pancreatic Cancer Patients
- SBP-101 is a Proprietary Polyamine Analogue Targeted Specifically for Pancreatic Diseases
- SBP-101 was Invented by Emeritus Professor Raymond Bergeron at the University of Florida in Gainesville, Florida, USA with World-Wide Exclusive Rights Licensed to Sun BioPharma, Inc.